Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Friedrich Haefele, PhD, is head of Biopharma Fill & Finish Germany for Boehringer Ingelheim.

Articles

Innovative therapeutic approaches beyond mAbs will require new methods for future facility construction.

Maturing Aseptic Technologies Create More Flexible Facilities

Steve Deakin is Business Development Director at I Holland.

Tool coatings are now seen as an acceptable means of solving production problems, such as sticking and corrosion, resulting in increased product yield.

Trends in Tablet Tooling

Tim Freeman is Managing Director of powder characterization company Freeman Technology for whom he has worked since the late 1990s. He was instrumental in the original design and continuing development of the FT4 Powder RheometerÂ® and through his work with various professional bodies, and involvement in industry initiatives, is an established contributor to wider developments in powder processing.Tim has a degree in Mechatronics from the University of Sussex in the UK. He is a mentor on a number of project groups for the Engineering Research Center for Structured Organic Particulate Systems in the US and a frequent contributor to industry conferences in the area of powder characterisation and processing. A past Chair of the American Association of Pharmaceutical Scientists (AAPS) Process Analytical Technology Focus Group Tim is a member of the Editorial Advisory Board of Pharmaceutical Technology and features on the Industry Expert Panel in European Pharmaceutical Review magazine. Tim is also a committee member of the Particle Technology Special Interest Group at the Institute of Chemical Engineers, Vice-Chair of the D18.24 sub-committee on the Characterization and Handling of Powders and Bulk Solids at ASTM and a member of the United States Pharmacopeial (USP) General Chapters Physical Analysis Expert Committee (GC-PA EC).

Efforts to tackle challenges in tablet manufacture are shaped by quality by design (QbD) and continuous manufacturing.

Tableting—a Focus for Continuous Improvement

Virginia Acha, DPhil, is director of regulatory policy, Europe, Middle East and Africa, at Amgen.

To realise the full potential for biosimilars, stakeholders must build a better understanding of biosimilars and to take a comprehensive view of how these important medicines can fit into treatment pathways.

Emerging Opportunities with Biosimilars

Stephen Tindal is director, Formulation and Site R&D Lead at Catalent Pharma Solutions.

Stephen Tindal from Catalent Pharma Solutions speaks with Pharmaceutical Technology Europe about advances in softgel technologies.

Opportunities with Softgels

Kaspar van den Dries, PhD, is senior director formulation sciences, solid dosage forms and softgels at Patheon.

Softgels are now being recognised as one of the preferred dosage forms for the treatment of pain, eye conditions, cough and cold, as well as allergy.

Past, Present and Future of Softgel Technologies

Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.

Technologies Key for Biologics to Meet Expectations

Representatives of contract service organizations that specialize in parenteral drug development and manufacturing describe the evolving trends.

CMOs Target Parenteral Drug Development Needs Both Large and Small

Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.

Solid-Dosage Forms Demand Traditional and Emerging Technologies

Pfizer announced an agreement to acquire Baxter International?s marketed vaccines for $635 million.